@article {Tano:December 2003:1473-7167:741,
	author = "Tano, Benoit",
	author = "Pathak, Dev",
	author = "Hoffmann, Stephen",
	title = "Cost-effectiveness of Advair: fluticasone propionate and salmeterol combination",
	journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
	volume = "3",
	year = "December 2003",
	abstract = "The National Heart, Lung and Blood Institute guidelines for the treatment of asthma suggest that inhaled corticosteroids, with the addition of a long-acting bronchodilator, may be the most effective long-term control medication for asthma. Five inhaled corticosteroids are approved for use in the USA, including beclomethasone dipropionate, budesonide, flunisolide, triamcinolone acetonide and fluticasone propionate. Fluticasone propionate (Flixotide<SUP>&#174;</SUP>) and the long-acting &#946;2 agonist salmeterol (Serevent<SUP>&#174;</SUP>), are now available in the USA together in an easy to use dry powder inhaler Advair<SUP>&#174;</SUP>. The cost-effectiveness of this combination in the treatment of persistent asthma is reviewed. This review evaluates all the cost-effectiveness studies comparing fluticasone propionate and salmeterol from two separate inhalers or one single inhaler available in the literature. Cost-effectiveness was compared with inhaled corticosteroids alone, leukotriene receptor antagonists and other combination therapies in patients with persistent asthma.",
	pages = "741-747(7)",
	url = "http://www.ingentaconnect.com/content/ftd/erp/2003/00000003/00000006/art00010"
	doi = "doi:10.1586/14737167.3.6.741"
}